Mekiri Bio Secures $1M Seed Funding for AI-Driven Genetic Medicine

Mekiri Bio has secured $1,000,000 in new investment capital from investors, a substantial achievement for the biotechnology firm focused on genetic medicine. This funding round underscores investor confidence in Mekiri Bio's innovative approach to overcome a critical bottleneck in therapeutic delivery. The company is at the forefront of developing advanced solutions, aiming to expand the reach of powerful genetic medicines like mRNA, CRISPR, and gene therapy beyond their current confinement to the liver. Currently, a major limitation in genetic medicine lies in the inability to effectively deliver these transformative therapies to specific organs other than the liver. Mekiri Bio addresses this challenge with its proprietary RAPTOR™ platform, an AI-driven system designed to make extrahepatic genetic medicine scalable. Unlike the slow, inefficient trial-and-error processes common in traditional biotech, the RAPTOR™ platform allows for the direct and cost-effective testing of hundreds of novel lipid nanoparticles (LNPs) in non-human primates (NHPs). This generates crucial real-world, human-relevant data at a significantly lower cost, promising to accelerate the development of more targeted and effective treatments. The recently secured capital will be strategically deployed to support Mekiri Bio's ongoing growth initiatives and further enhance the development of its RAPTOR™ platform. This investment is anticipated to accelerate research and development efforts, allowing the company to refine its technology and potentially expand its scientific and operational capabilities. Mekiri Bio aims to leverage this funding to solidify its leadership in extrahepatic genetic medicine delivery, ultimately paving the way for a new generation of targeted genetic therapies that can reach any organ and improve patient outcomes globally.